Skip to search formSkip to main contentSkip to account menu

Casodex

Known as: AstraZeneca brand of bicalutamide, Zeneca brand of bicalutamide, Astra brand of bicalutamide 
National Institutes of Health

Related topics

Related topics

2 relations
ICI-176334

Broader (1)

bicalutamide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage…
Despite androgen deprivation therapy (ADT) suppression of prostate cancer (PCa) growth, its overall effects on PCa metastasis… 
Highly Cited
2012
Highly Cited
2012
Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen‐sensitive prostate cancer cells
Androgen deprivation therapy, one of the standard treatments for prostate cancer (PCa) induces apoptosis, as well as autophagy in… 
Highly Cited
2007
Highly Cited
2007
A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells
Prostate tumors are initially dependent on androgens for growth, but the majority of patients treated with anti-androgen therapy… 
Highly Cited
2007
Highly Cited
2007
Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose…
Highly Cited
2000
Highly Cited
2000
Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells.
An expression construct containing the cDNA encoding a modified aequorea green fluorescent protein (GFP) ligated to the 5'-end of… 
Highly Cited
1999
Highly Cited
1999
Rapid signalling by androgen receptor in prostate cancer cells
Androgens are important growth regulators in prostate cancer. Their known mode of action in target cells requires binding to a… 
Review
1998
Review
1998
Bicalutamide (Casodex®) in the treatment of prostate cancer: History of clinical development
Bicalutamide (Casodex®) is a new nonsteroidal antiandrogen developed for use in patients with prostate cancer. The efficacy and… 
Highly Cited
1996
Highly Cited
1996
Enantioselective binding of Casodex to the androgen receptor.
1. The biologic activity of androgens is mediated through the formation of a non-covalent androgen receptor (AR)-steroid complex… 
Highly Cited
1995
Highly Cited
1995
Withdrawal phenomenon with the antiandrogen casodex.
Total androgen blockade with castration and antiandrogens has become the primary therapy in metastatic prostate carcinoma… 
Highly Cited
1994
Highly Cited
1994
Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer
OBJECTIVE Casodex (Zeneca) is a new potent, long‐acting non‐steroidal anti‐androgen, which produces androgen deprivation by… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)